The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models
Open Access
- 15 June 2017
- journal article
- research article
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (6)
Abstract
Glioblastoma is the most frequent and the most lethal primary brain tumor among adults. Standard of care is the association of radiotherapy with concomitant or adjuvant temozolomide. However, to date, recurrence is inevitable. The CXCL12/CXCR4 pathway is upregulated in the glioblastoma tumor microenvironment regulating tumor cell proliferation, local invasion, angiogenesis, and the efficacy of radio-chemotherapy. In this study, we evaluated the effects of the novel CXCR4 antagonist, PRX177561, in preclinical models of glioblastoma. CXCR4 expression and PRX177561 effects were assessed on a panel of 12 human glioblastoma cells lines and 5 patient-derived glioblastoma stem cell cultures. Next, the effect of PRX177561 was tested in vivo, using subcutaneous injection of U87MG, U251, and T98G cells as well as orthotopic intrabrain inoculation of luciferase-transfected U87MG cells. Here we found that PRX177561 impairs the proliferation of human glioblastoma cell lines, increases apoptosis, and reduces CXCR4 expression and cell migration in response to stromal cell–derived factor 1alpha in vitro. PRX177561 reduced the expression of stem cell markers and increased that of E-cadherin and glial fibrillary acidic protein in U87MG cells consistent with a reduction in cancer stem cells. In vivo, PRX177561 reduced the weight and increased the time to progression of glioblastoma subcutaneous tumors while increasing disease-free survival and overall survival of mice bearing orthotopic tumors. Our findings suggest that targeting stromal cell–derived factor 1 alpha/CXCR4 axis by PRX177561 might represent a novel therapeutic approach against glioblastoma and support further investigation of this compound in more complex preclinical settings in order to determine its therapeutic potential.Keywords
This publication has 50 references indexed in Scilit:
- Immunohistochemical expression of stem cell markers CD44 and nestin in glioblastomas: Evaluation of their prognostic significancePathology - Research and Practice, 2016
- Migrating glioma cells express stem cell markers and give rise to new tumors upon xenograftingJournal of Neuro-Oncology, 2016
- Human glioblastoma‐associated microglia/monocytes express a distinct RNA profile compared to human control and murine samplesGlia, 2016
- Limited role for transforming growth factor–β pathway activation-mediated escape from VEGF inhibition in murine glioma modelsNeuro-Oncology, 2016
- CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and MacrophagesCancer Research, 2016
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survivalProceedings of the National Academy of Sciences, 2016
- Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotypeJCI Insight, 2016
- Primary brain tumours in adultsThe Lancet, 2012
- Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human GlioblastomaCancer Research, 2004
- Temozolomide as Second-line Chemotherapy for Relapsed GliomasJournal of Neuro-Oncology, 2002